TY  - JOUR
T1  - Formulation, Development, and Evaluation of Quetiapine Fumarate Immediate Release Tablets
A1  - Prashant Lakshaman Pingale
A1  - Sahebrao Sampat Boraste
A1  - Sunil Vishvanath Amrutkar
JF  - Pharmacophore
JO  - Pharmacophore
SN  - 2229-5402
Y1  - 2021
VL  - 12
IS  - 6
DO  - 10.51847/qO6nwFnunI
SP  - 72
EP  - 81
N2  - Antipsychotic medications can help control the symptoms of schizophrenia. A variety of scientific and demographic factors show the capability to sway the selection of odd neuroleptic medications. Quetiapine Fumarate is indicated for the treatment of schizophrenia and bipolar disorder. Disintegrating agents are materials that are commonly used in the formulation of tablets and hard-shell capsules. Within a short period after administration, drugs should dissolve or disintegrate in the stomach. The most preferred decomposition agent in the making of tablets is starch. The primary purpose of this research was to create a reliable immediate-release tablet formulation of the antipsychotic Quetiapine. Tablets are popular due to their low cost, packaging, and shipping, as well as their greater stability and virtual tamper resistance. Orally administered tablets with a faster disintegration time have a shorter absorption time and higher bioavailability. The goal of the study is to create a stable and physically and chemically compatible generic formulation for treating schizophrenia, as well as a pharmaceutically equivalent instant release tablet for individuals with mental illnesses like schizophrenia and bipolar disorder.
UR  - https://pharmacophorejournal.com/article/formulation-development-and-evaluation-of-quetiapine-fumarate-immediate-release-tablets-gfmchs07ghtysze
ER  -